Skip to content

Comparative study of Siddharthak Gel and Siddharthak Lepa in patients suffering from Dadrukushtha (Tinea?Corporis)

Randomized Controlled Clinical Trial to evaluate the efficacy of Siddharthak Gel over Siddharthak Lepa in the management of Dadrukushtha (Tinea Corporis) - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/093984
Enrollment
80
Registered
2025-09-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B354- Tinea corporis

Interventions

None listed

Sponsors

Dr Ajit Vijaykumar Patil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age: - 20 to 50 years age of group participants irrespective of Gender Religion Socio-economic and Marital Status suffering from dadrukushtha (Tinea corporis) 2) Participant assessed and diagnosed thoroughly based on Ayurvedic classical signs & symptoms of dadrukushtha 3) Participant having multiple lesions of dadrukushtha on body

Exclusion criteria

Exclusion criteria: 1) Known participant with history of other systemic disorders like diabetes mellitus HIV Tuberculosis etc 2) Participant?s receiving prolonged immunosuppressant and antibiotic therapy 3) Known participant having history of Chronic and severe cases associated with complications or secondary infection 4) Treated case & those who were received topical antifungal treatment within 1 week before baseline visit 5) Participant Currently receiving anti-fungal treatments like systemic or local 6) Participant suffering from other skin diseases than dadru like psoriasis, herpes etc

Design outcomes

Primary

MeasureTime frame
Global Assessment Score (GAS) based on the evaluation of six signs and symptoms of Dadrukushtha (Tinea Corporis): ?Kandu (itching) ?Raga (redness) ?Visarpana (spreading of lesion) ?Tamra Varna (coppery discoloration) ?Pidaka (papular eruptions) ?Mandala (number and size of circular lesions) Each parameter will be assessed using a 0?3 severity scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe). The total GAS will be calculated by summing the scores of all parameters (Range: 0?18).Timepoint: ?Day 0 (Baseline) ?Day 7 (First Follow-up) ?Day 15 (End?of?Treatment)

Secondary

MeasureTime frame
DLQI (Dermatology Life Quality Index) ScoreTimepoint: Day 0, Day 15

Countries

India

Contacts

Public ContactDr Ajit Vijaykumar Patil

Tilak Ayurved Mahavidyalaya Pune

manvantar@gmail.com9822435536

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026